T-Cell Engagers in Autoimmune Disease: China’s Origination Advantage
2026
China now supplies the T-cell engager pipeline reshaping autoimmune disease, but the evidence base hasn’t caught up with the capital. This report tracks eleven direct China-origin transactions worth up to USD 8.6 billion in headline consideration, set against a peer-reviewed human safety and efficacy record of fewer than 90 patients.
It explains why deep B-cell depletion is drawing comparisons to ex vivo CAR-T, what separates the molecules acquirers are actually paying for (CD3 engineering, not target selection), and where the real commercial risk sits: immunoglobulin loss, re-treatment, and whether a regimen can be delivered outside a hospital at a price health systems will reimburse.
Drawing on primary trial data, conference disclosures and deal terms across CD19, CD20 and BCMA programs, Selesta’s analysts identify where the pipeline is genuinely de-risked, where it isn’t, and which unpartnered assets carry the most interesting near-term optionality.
China now supplies the T-cell engager pipeline reshaping autoimmune disease, but the evidence base hasn’t caught up with the capital. This report tracks eleven direct China-origin transactions worth up to USD 8.6 billion in headline consideration, set against a peer-reviewed human safety and efficacy record of fewer than 90 patients.
It explains why deep B-cell depletion is drawing comparisons to ex vivo CAR-T, what separates the molecules acquirers are actually paying for (CD3 engineering, not target selection), and where the real commercial risk sits: immunoglobulin loss, re-treatment, and whether a regimen can be delivered outside a hospital at a price health systems will reimburse.
Drawing on primary trial data, conference disclosures and deal terms across CD19, CD20 and BCMA programs, Selesta’s analysts identify where the pipeline is genuinely de-risked, where it isn’t, and which unpartnered assets carry the most interesting near-term optionality.
Sharing Link
or sharing via
